Brief: Ipsen: Phase II Falkon Trial Did Not Meet Primary Endpoint

Ipsen SA

19/12/2025 06:04

Dec 19 (Reuters) - Ipsen SA IPN.PA:

UPDATE ON PHASE II FALKON TRIAL IN PATIENTS WITH ULTRA-RARE BONE DISEASE, FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)

STUDY CLOSED; FIDRISERTIB WELL TOLERATED WITH NO SAFETY CONCERNS

PHASE II FALKON TRIAL DID NOT MEET ITS PRIMARY ENDPOINT OF REDUCING NEW HETEROTOPIC OSSIFICATION

Source text: ID:nGNE6dYt2W

Further company coverage: IPN.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))